TY - JOUR
T1 - BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma
AU - Gaitonde, Supriya
AU - De, Surya K.
AU - Tcherpakov, Marianna
AU - Dewing, Antimone
AU - Yuan, Hongbin
AU - Riel-Mehan, Megan
AU - Krajewski, Stan
AU - Robertson, Gavin
AU - Pellecchia, Maurizio
AU - Ronai, Ze'Ev
PY - 2009/4
Y1 - 2009/4
N2 - Summary The AKT/PKB pathway plays a central role in tumor development and progression and is often up-regulated in different tumor types, including melanomas. We have recently reported on the in silico approach to identify putative inhibitors for AKT/PKB. Of the reported hits, we selected BI-69A11, a compound which was shown to inhibit AKT activity in in vitro kinase assays. Analysis of BI-69A11 was performed in melanoma cells, a tumor type that commonly exhibits up-regulation of AKT. Treatment of the UACC903 human melanoma cells, harboring the PTEN mutation, with BI-69A11 caused efficient inhibition of AKT S473 phosphorylation with concomitant inhibition of AKT phosphorylation of PRAS40. Treatment of melanoma cells with BI-69A11 also reduced AKT protein expression, which coincided with inhibition of AKT association with HSP-90. BI-69A11 treatment not only caused cell death of melanoma, but also prostate tumor cell lines. Notably, the effect of BI-69A11 on cell death was more pronounced in cells that express an active form of AKT. Significantly, intra-peritoneal injection of BI-69A11 caused effective regression of melanoma tumor xenografts, which coincided with elevated levels of cell death. These findings identify BI-69A11 as a potent inhibitor of AKT that is capable of eliciting effective regression of xenograft melanoma tumors.
AB - Summary The AKT/PKB pathway plays a central role in tumor development and progression and is often up-regulated in different tumor types, including melanomas. We have recently reported on the in silico approach to identify putative inhibitors for AKT/PKB. Of the reported hits, we selected BI-69A11, a compound which was shown to inhibit AKT activity in in vitro kinase assays. Analysis of BI-69A11 was performed in melanoma cells, a tumor type that commonly exhibits up-regulation of AKT. Treatment of the UACC903 human melanoma cells, harboring the PTEN mutation, with BI-69A11 caused efficient inhibition of AKT S473 phosphorylation with concomitant inhibition of AKT phosphorylation of PRAS40. Treatment of melanoma cells with BI-69A11 also reduced AKT protein expression, which coincided with inhibition of AKT association with HSP-90. BI-69A11 treatment not only caused cell death of melanoma, but also prostate tumor cell lines. Notably, the effect of BI-69A11 on cell death was more pronounced in cells that express an active form of AKT. Significantly, intra-peritoneal injection of BI-69A11 caused effective regression of melanoma tumor xenografts, which coincided with elevated levels of cell death. These findings identify BI-69A11 as a potent inhibitor of AKT that is capable of eliciting effective regression of xenograft melanoma tumors.
UR - http://www.scopus.com/inward/record.url?scp=62149090949&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=62149090949&partnerID=8YFLogxK
U2 - 10.1111/j.1755-148X.2009.00544.x
DO - 10.1111/j.1755-148X.2009.00544.x
M3 - Article
C2 - 19175524
AN - SCOPUS:62149090949
SN - 1755-1471
VL - 22
SP - 187
EP - 195
JO - Pigment Cell and Melanoma Research
JF - Pigment Cell and Melanoma Research
IS - 2
ER -